




China Cord Blood Corporation (NYSE : CO)

Corporate Presentation - August 2013



Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company's future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions; uncertainties and other factors may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this presentation is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date of this presentation, and the Company does not intend to update any of the forward-looking statements after the date of this presentation to conform these statements to actual results, unless required by law.

The forward-looking statements included in this presentation are subject to risks, uncertainties and assumptions about the Company's businesses and business environments. These statements reflect the Company's current views with respect to future events and are not a guarantee of future performance. Actual results of the Company's operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People's Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company's different pricing and payment options and reaction to the introduction of the Company's premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company's ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a "reverse merger" with an operating company based in China, as well as general economic conditions; compliance with restrictive debt covenants under our senior convertible notes; and other relevant risks detailed in the Company's filings with the Securities and Exchange Commission in the United States.

Company Overview

China Cord Blood Corporation is a leading cord blood banking operator in China, providing cord blood stem cell processing and storage services for subscribers exclusively in Beijing municipality, Guangdong province, and Zhejiang province

Leading Market Presence	<ul style="list-style-type: none">■ First and largest operator in China, with longest track record■ The only operator with multiple licenses, with access to 4* of the 7 authorized licenses
Dominant Operator	<ul style="list-style-type: none">■ Exclusive operations in Beijing, Guangdong and Zhejiang markets, covering 45% of total newborns within all authorized regions⁽¹⁾■ Largest newborn population coverage among authorized regions
Proven Effective Business Model & Execution Capabilities	<ul style="list-style-type: none">■ Lucrative and recurring revenue model■ Rising brand recognition and well-executed strategies driving penetration■ Experienced management team

Our Services

Cord Blood Collection

Separation & Extraction

Lab Testing & Validation

Storage


Notes:

⁽¹⁾ According to 2011 data in the National Bureau of Statistics of China

* Equity investment in Shandong Cord Blood Bank

Subscription-based Business Model

- Provide fee-based storage services for subscribers who choose to store cord blood stem cell for potential use in the future
- Typical storage agreement is 18 years
- Subscription fees consist of two components -- processing fee (RMB6,800) & annual storage fee (RMB860/year)



+

- Infants automatically enroll into a general medical insurance provided by 3rd party insurance provider (general medical insurance coverage for out-patient and in-patient, and transplant costs)

Notes:

Customers have the right to terminate their subscription agreements with us prior to the end of the 18-year term, and the children have the option of continuing them beyond 18 years

Lucrative & Recurring Revenue Model

The recurring revenue model builds a solid payment structure for a steady stream of long-term revenue inflow


Processing Fee

- Generation of substantial upfront cash flow
- Growth driven by increase in new subscriber numbers


Storage Fee

- Annuity-like recurring storage fees
- Increasing storage fee revenue as subscriber base continues to grow
- Economy of scales, small incremental cost to store one additional sample

Breakdown of Fee Components as % of Total Revenue



Total Subscribed Units Stored



Notes: Fiscal year ended March 31

Enormous Addressable Market

Cord blood banking licenses in China



CCBC is the only operator with multiple licenses

Sources:

– National Bureau of Statistics of China

Notes:

⁽¹⁾ 3 additional licenses can be issued in other regions

⁽²⁾ Represents direct-controlled municipalities, which are cities

⁽³⁾ Equity investment

Largest Newborn Population Coverage Among Authorized Regions

Province / Municipality ⁽¹⁾	2011 Newborn Population	Percentage of Total (%)
Beijing ⁽²⁾	167,000	4%
Guangdong	1,098,000	28%
Zhejiang	517,000	13%
Shandong ⁽³⁾	1,108,000	28%
Tianjin ⁽²⁾	116,000	3%
Shanghai ⁽²⁾	164,000	4%
Sichuan	788,000	20%
Total	3,958,000	100%

 Denotes CCBC presence

- A total of 31 regions in China, only 7 of which were authorized to provide cord blood banking services. There are 16.1 million babies born in China and 7 regions represent approx. 25% of China's total.

Favorable Industry Dynamics

Single Child Policy

- Parents in the targeted segments are more likely to devote more resources for the benefits of their only child
- Urbanization continues to lift the total babies born in cities and metropolitan areas

“One License per Region” Policy

- Licensee is the exclusive operator in the respective region
- Extremely high entry barriers & rigorous requirements

Increasing Public Awareness

- Benefits associated with cord blood banking services and stem cell therapies are increasingly recognized
- Large subscriber base helps attract more clients
- Families spend increasing amount of disposable income on healthcare

Huge Population Base ⁽¹⁾

- China's newborn population is about 4 times more than the U.S.
- Beijing has a market size similar to NYC, Guangdong's market size is about 9 times of NYC or twice the size of the state of California, and Zhejiang's newborn number is about the same as the state of California and more than 4 times of NYC

Highly Regulated Industry

Licensing Regime

- Under the “One License per Region” policy, only one cord blood banking license is issued in any region
- The Ministry of Health will only issue up to 10 licenses in 10 different provinces or municipalities before 2015
- Only 7 licenses have been issued in China as of today
- It takes numerous years to complete the application process with stringent requirements
 - Laboratories comply with national standards
 - Collection of minimum number of donated samples and preserved for a certain time period
 - Successfully completed required number of transplants
- Significant upfront financial commitment

Lengthy Application Process

Commence application process



Construction of facility meeting various national standards



Collection of samples




Fulfilling transplant requirements




License granted subject to successful completion of the review process

Consistent Quarterly Subscriber Growth

New Subscriber Sign-ups




Total Subscribed Units Stored




Notes: Fiscal year ended March 31

Substantial Profitability & Robust Cashflow

Revenue & Operating Profit



Operating Profit & Operating Cashflow



Notes: Fiscal year ended March 31

Recent Corporate Developments

Strengthening Our Position to Meet Our Business Objectives

Beijing Cord Blood Bank received AABB Accreditation

Capacity expansion in Guangdong

Construction of Zhejiang facility in full swing

Upward Price Adjustment since April 2013

Partnership with KKR to fuel our growth and development for further domestic expansion, deeper penetration, and potential M&A opportunities

Continue share buyback program

Capable Management Team

Extensive healthcare experiences & abilities to commercialize and expand our services

Mr. Yuen Kam
Chairman

- Oversees the strategic direction of CCBC
- 20+ years of experience in China's healthcare industry

Ms. Ting Zheng
Chief Executive Officer and Director

- Actively involved in establishment of cord blood banking operations since 2003
- 10+ years of experience in the field of corporate strategy in China's healthcare industry

Mr. Albert Chen
Chief Financial Officer and Director

- 10+ years of experience in the pharmaceutical and healthcare industries
- CFA charter holder

Ms. Yue Deng
Chief Executive Officer – Beijing Division

- 10+ years of managerial, sales and marketing experiences working in Guidant's Beijing representative office
- Worked at NOX international from 1993 to 1995

Ms. Rui Arashiyama
Chief Executive Officer – Guangdong and Zhejiang Divisions

- 10+ years of sales and marketing experiences in China
- Worked at Nissan from 1989 to 1999, responsible for overseas market development including China, Hong Kong and Singapore

Ms. Xin Xu
Chief Technology Officer

- 20+ years of solid experience in Cryobiology research
- Lectured Cryobiology at Beijing Medical University

Seasoned
Management Team
with Extensive
Experience

In-depth
Knowledge of the
China Healthcare
Services Sector

Successful Track
Record on
Acquisition and
Commercialization

Income Statement (US GAAP)

Summary of Income Statement

(in thousands)	Three months ended June 30,		
	2012	2013	2013
	RMB	RMB	US\$
Revenues	115,330	128,721	20,974
Gross profit	90,941	104,229	16,983
Research and development	(2,263)	(2,523)	(411)
Sales and marketing	(19,220)	(28,424)	(4,631)
General and administrative	(25,060)	(27,402)	(4,465)
Operating income	44,398	45,880	7,476
Other expense, net	(4,181)	(1,448)	(237)
Interest expense	(10,176)	(14,758)	(2,405)
Income tax expense	(6,335)	(11,373)	(1,853)
Net income attributable to the Company	31,093	32,906	5,361
<i>*Depreciation and amortization</i>	<i>7,921</i>	<i>8,593</i>	<i>1,400</i>

Notes: Only key line items are shown

Balance Sheet (US GAAP)

Selected Cash Flow Statements Items

	Three Months Ended June 30, 2012	Three Months Ended June 30, 2013	
(in thousands)	RMB	RMB	US\$
Net cash provided by operating activities	136,872	108,654	17,704
Net cash used in investing activities	(82,528)	(39,360)	(6,413)
Net cash provided by/(used in) financing activities	299,046	(3,242)	(528)

Selected Balance Sheet Items

	March 31, 2013	June 30, 2013	
(in thousands)	RMB	RMB	US\$
Cash and cash equivalents	1,494,099	1,560,024	254,184
Working capital ⁽¹⁾	1,265,726	1,353,398	220,515
Total assets	2,986,276	3,106,279	506,123
Bank loan	50,000	50,000	8,147
Convertible notes	751,781	750,086	122,216
Total shareholders' equity	1,237,132	1,301,181	212,008

Notes:

- Only key line items are shown

- Fiscal year ended March 31

⁽¹⁾ Current assets less current liabilities